Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

The cyclic AMP pathway is a sex-specific modifier of glioma risk in type 1 neurofibromatosis patients.

Warrington NM, Sun T, Luo J, Mckinstry RC, Parkin PC, Ganzhorn S, Spoljaric D, Albers AC, Merkelson A, Stewart DR, Stevenson DA, Viskochil D, Druley TE, Forys JT, Reilly KM, Fisher MJ, Tabori U, Allen JC, Schiffman J, Gutmann DH, Rubin JB.

Cancer Res. 2014 Nov 7. pii: canres.1891.2014. [Epub ahead of print]

PMID:
25381154
[PubMed - as supplied by publisher]
2.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic Myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Oct 21. pii: canres.0876.2014. [Epub ahead of print]

PMID:
25336188
[PubMed - as supplied by publisher]
3.

Quantitative analysis of F-actin redistribution in astrocytoma cells treated with candidate pharmaceuticals.

Lockett S, Verma C, Brafman A, Gudla P, Nandy K, Mimaki Y, Fuchs PL, Jaja J, Reilly KM, Beutler J, Turbyville TJ.

Cytometry A. 2014 Jun;85(6):512-21. doi: 10.1002/cyto.a.22442. Epub 2014 Feb 11.

PMID:
24515854
[PubMed - in process]
4.

Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.

Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.

Phytochem Lett. 2014 Feb 1;7:42-45.

PMID:
24443661
[PubMed]
5.

Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.

PLoS One. 2013 Jun 6;8(6):e65801. doi: 10.1371/journal.pone.0065801. Print 2013.

PMID:
23762429
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Extending the convergence of canonical WNT signaling and classic cancer pathways for treatment of malignant peripheral nerve sheath tumors.

Reilly KM.

Cancer Discov. 2013 Jun;3(6):610-2. doi: 10.1158/2159-8290.CD-13-0192.

PMID:
23749527
[PubMed - indexed for MEDLINE]
7.

Process and outcomes of patient-centered medical care with Alaska Native people at Southcentral Foundation.

Driscoll DL, Hiratsuka V, Johnston JM, Norman S, Reilly KM, Shaw J, Smith J, Szafran QN, Dillard D.

Ann Fam Med. 2013 May-Jun;11 Suppl 1:S41-9. doi: 10.1370/afm.1474.

PMID:
23690385
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth.

Devkota KP, Wilson J, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.

J Nat Prod. 2013 Jan 25;76(1):59-63. doi: 10.1021/np300696g. Epub 2012 Dec 26.

PMID:
23268719
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.

Amlin-Van Schaick JC, Kim S, DiFabio C, Lee MH, Broman KW, Reilly KM.

Neuro Oncol. 2012 Feb;14(2):160-74. doi: 10.1093/neuonc/nor206. Epub 2012 Jan 10.

PMID:
22234937
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

Amlin-Van Schaick J, Kim S, Broman KW, Reilly KM.

Mamm Genome. 2012 Apr;23(3-4):277-85. doi: 10.1007/s00335-011-9380-0. Epub 2011 Dec 8.

PMID:
22160242
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.

Gürsel DB, Connell-Albert YS, Tuskan RG, Anastassiadis T, Walrath JC, Hawes JJ, Amlin-Van Schaick JC, Reilly KM.

Neuro Oncol. 2011 Jun;13(6):610-21. doi: 10.1093/neuonc/nor035.

PMID:
21636709
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Back to the future: proceedings from the 2010 NF Conference.

Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu Y, Hunter-Schaedle K, Giancotti FG.

Am J Med Genet A. 2011 Feb;155A(2):307-21. doi: 10.1002/ajmg.a.33804. Epub 2010 Dec 22.

PMID:
21271647
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.

Turbyville TJ, Gürsel DB, Tuskan RG, Walrath JC, Lipschultz CA, Lockett SJ, Wiemer DF, Beutler JA, Reilly KM.

Mol Cancer Ther. 2010 May;9(5):1234-43. doi: 10.1158/1535-7163.MCT-09-0834. Epub 2010 May 4.

PMID:
20442305
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Genetically engineered mouse models in cancer research.

Walrath JC, Hawes JJ, Van Dyke T, Reilly KM.

Adv Cancer Res. 2010;106:113-64. doi: 10.1016/S0065-230X(10)06004-5. Review.

PMID:
20399958
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency.

Pemov A, Park C, Reilly KM, Stewart DR.

BMC Genomics. 2010 Mar 22;11:194. doi: 10.1186/1471-2164-11-194.

PMID:
20307317
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis.

Hawes JJ, Reilly KM.

Toxicol Pathol. 2010 Jan;38(1):123-30. doi: 10.1177/0192623309357075.

PMID:
20176786
[PubMed - indexed for MEDLINE]
Free Article
17.

The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.

Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH.

Cancer Res. 2010 Feb 15;70(4):1356-66. doi: 10.1158/0008-5472.CAN-09-2178. Epub 2010 Feb 2.

PMID:
20124472
[PubMed - indexed for MEDLINE]
Free Article
18.

Neurofibromatosis and lessons for the war on cancer.

Reilly KM.

EMBO Mol Med. 2009 Jul;1(4):198-200. doi: 10.1002/emmm.200900029.

PMID:
20049721
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner.

Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quiñones OA, Reilly KM.

Mamm Genome. 2009 Apr;20(4):214-23. doi: 10.1007/s00335-009-9179-4. Epub 2009 Apr 4.

PMID:
19347398
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.

Reilly KM, Kisor DF.

Onco Targets Ther. 2009 Feb 18;2:219-28.

PMID:
20616909
[PubMed]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk